proliferative diabetic retinopathy
Ophthalmology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ranibizumab Treatment of proliferative diabetic retinopathy (PDR) with or without diabetic macular oedema (DMO). The PBAC expanded the requested indication from PDR… | May 2025 | Recommended with restriction | input received Macular Disease Foundation Australia |
Who spoke
Macular Disease Foundation Australia
What the PBS pays
$92M in government benefit over 2024–25, across 105,633 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ranibizumab | $91.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.